A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2023-04-20
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-05-15 (study day 14); relationship: not assessed
moderate
assessed
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2024-01-24 (study day 268); relationship: not assessed
moderate
assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-10-22 (study day 540); relationship: not assessed
Data queries
No data queries.